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Tetratricopeptide repeat domain 
9A modulates anxiety-like behavior 
in female mice
Lee Wei Lim1,*, Smeeta Shrestha2,*, Yu Zuan Or2, Shawn Zheng Kai Tan1, Hwa Hwa Chung2, 
Yang Sun2, Chew Leng Lim2, Sharafuddin Khairuddin1, Thomas Lufkin3 & 
Valerie Chun Ling Lin2
Tetratricopeptide repeat domain 9A (TTC9A) expression is abundantly expressed in the brain. Previous 
studies in TTC9A knockout (TTC9A−/−) mice have indicated that TTC9A negatively regulates the 
action of estrogen. In this study we investigated the role of TTC9A on anxiety-like behavior through 
its functional interaction with estrogen using the TTC9A−/− mice model. A battery of tests on anxiety-
related behaviors was conducted. Our results demonstrated that TTC9A−/− mice exhibited an increase 
in anxiety-like behaviors compared to the wild type TTC9A+/+ mice. This difference was abolished after 
ovariectomy, and administration of 17-β-estradiol benzoate (EB) restored this escalated anxiety-like 
behavior in TTC9A−/− mice. Since serotonin is well-known to be the key neuromodulator involved in 
anxiety behaviors, the mRNA levels of tryptophan hydroxylase (TPH) 1, TPH2 (both are involved in 
serotonin synthesis), and serotonin transporter (5-HTT) were measured in the ventromedial prefrontal 
cortex (vmPFC) and dorsal raphe nucleus (DRN). Interestingly, the heightened anxiety in TTC9A−/− mice 
under EB influence is consistent with a greater induction of TPH 2, and 5-HTT by EB in DRN that play key 
roles in emotion regulation. In conclusion, our data indicate that TTC9A modulates the anxiety-related 
behaviors through modulation of estrogen action on the serotonergic system in the DRN.
Mood and anxiety disorders are the most common mental illnesses with a lifetime prevalence as high as 20%1,2. 
It has been reported that women have a higher rate to develop this disorder with twice the risk than men3. In par-
ticular, the higher incidence of female suffering from mood and anxiety disorder is mainly related to hormonal 
cycle changes, family responsibility, work pressure, and comorbidity from somatic illnesses4,5. Although no spe-
cific etiology that causes mood and anxiety has been identified, it is likely that genetic, biological, environmental, 
and lifestyle factors may play a major role in its pathophysiology.
Mood and anxiety disorders can be treated effectively by either medication, usually targeting the serotonin-
ergic (5-hydroxytryptamine, 5-HT) system, and/or psychotherapy. The dysfunction of 5-HT neurotransmission 
has long been associated with major depressive disorder, anxiety, and suicidal behavior6,7. In clinical and exper-
imental studies, pathological alterations of the amino acid tryptophan hydroxylase (TPH, a precursor for the 
biosynthesis of serotonin) and the 5-HT transporters (5-HTT) have been reported to either functionally increase 
or reduce 5-HT neurotransmission in specific area of the limbic and frontal regions7–9. Of particular interest, 
reduction of TPH and 5HTT in ventromedial prefrontal cortex (vmPFC) and increased 5-HTT in dorsal raphe 
nucleus (DRN) is associated with mood- and anxiety-like behavior in animal models8,9.
Tetratricopeptide repeat domain 9A (TTC9A) was first isolated from a brain cDNA library10, and it shares 
significant homology with FK506 Binding Proteins (FKBP) cyclophilin 40, FKBP51, FKBP52 and FKBP38 that 
are steroid receptor co-chaperones involved in modulating steroid receptor assembly and maturation11,12. TTC9A 
protein contains 3 tetratricopeptide repeat (TPR) domains that are 34 amino acid consensus motif present in 
varying numbers in a large family of TPR-containing proteins11,13. These TPR motifs in tandem arrays form 
antiparallel α -helical hairpins that serve as an important protein interaction interface and are involved in regulat-
ing diverse biological processes including steroid receptor signaling11,14.
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TTC9A is expressed in the mouse embryonic stem cells15. In situ hybridization study of mouse embryos at 
day 13.5 showed abundant TTC9A expression only in the neural tissues (Fig. 1). TTC9A protein is ubiquitously 
expressed in all tissues after birth, with the highest expression in the brain and the lowest expression in the 
liver15,16. TTC9A expression is regulated by both estrogen and progesterone in breast cancer cells. It is drasti-
cally induced by progesterone in progesterone receptor-transfected breast cancer cells MDA-MB-231 which also 
exhibited16, growth inhibition and focal adhesion in these cells17,18; its expression is down-regulated by the estro-
gen in MCF7 breast cancer cells16. These data seem to suggest a negative association between TTC9A expression, 
cell growth and the involvement of TTC9A in ovarian steroid hormone signaling in human breast cancer cells. 
However, studies in mice revealed that estrogen significantly up-regulated the TTC9A expression in estrogen 
target tissues such as the uterus and mammary gland15.
Estrogen has been implicated in the regulation of emotion within the limbic system19. Earlier studies have 
consistently shown that the fluctuation of estrogen during puberty, pregnancy, and pre-or post-menopause peri-
ods increased the risk of developing mood and anxiety disorders, and cognitive dysfunction20. TTC9A has been 
shown to negatively regulate estrogen activity in TTC9A knockout (TTC9A−/−) mice15,21. In this study, we inves-
tigated the role of TTC9A on mood- and anxiety-related behaviors using the TTC9A−/− mice model. A battery 
of behavior tests on anxiety, memory function, social behavior, hedonia, and behavioral despair were conducted. 
The study found that TTC9A−/− female mice were more anxious as compared to wildtype (TTC9A+/+) mice and 
the phenotype appears to be due to the difference in response to 17-β -estradiol benzoate (EB) treatment. The anx-
ious phenotype in TTC9A−/− mice is associated with greater induction of TPH2 and 5-HTT by EB administration 
that positively influences the serotonergic system. These findings indicate for the first time that TTC9A modulates 
anxiety-related behaviors through negative regulation of estrogen action on serotonergic system in the DRN.
Figure 1. Visualization of TTC9A expression in the developmental embryonic stage. TTC9A expression 
in TTC9A+/+ mice embryo day 13.5 visualized by RNA-ISH. In-situ hybridization with the control probe 
(A–C) and with the TTC9A probe (D–F). The parasagittal lateral (A,D) section through the embryo at 13X 
magnification power show TTC9A expression in the forebrain (FB) and retina (RE), and parasagittal medial 
section (B,E) show TTC9A expression in the forebrain (FB), hindbrain (HB), Rathke’s pouch (RP) and the 
dorsal root ganglion (DRG). The E13.5 mid sagittal section shows TTC9A mRNA expression at the forebrain 
(FB), hind brain (HB), mid brain (MB), Rathke’s pouch (RP), dorsal root ganglion (DRG), and around the main 
bronchus (MBR).
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Results
TTC9A−/− mice exhibit increased anxiety-like behaviors. In the anxiety tests, there were significant 
effects of increased latency of TTC9A−/− female mice to escape from their home-cage (t(8) = 3.113, p = 0.014; 
Fig. 2B) in the home-cage emergence test, and increased immobility (t(7) = 4.942, p = 0.002; Fig. 2D) in the rat-
cage behavior test as compared to the TTC9A+/+ female mice. In addition, a reduction of exploratory rearing was 
consistently found in both the novel-cage exploratory test (t(7) = − 2.408, p = 0.047; Fig. 2C) and rat-cage behavior 
test (t(7) = − 5.043, p = 0.001; Fig. 2E) of TTC9A−/− female mice as compared to the TTC9A+/+ animals. On the 
other hand, analysis of the male mice showed no significant difference in the escape latency of home-cage emer-
gence test (t(13) = 0.245, p = n.s.; Fig. 3A), immobility (t(13) = − 0.492, p = n.s.) and rearing (t(13) = 1.815, p = n.s.) 
behaviors in the rat-cage behavior test (Fig. 3C,D) between the TTC9A−/− and TTC9A+/+ animals. However, a 
slight increase of rearing behavior (t(12) = 2.292, p = 0.041) was found in the TTC9A−/− male mice in the nov-
el-cage exploration test (Fig. 3B).
TTC9A knockout did not affect memory function. In the object-recognition test, a repeated-measures 
analysis showed no significant difference between TTC9A+/+ and TTC9A−/− mice for group (F(1,8–10) < 3.371, 
p = n.s.) and their interaction group × exploration level (F(1,8–10) < 1.158, p = n.s.) in both the female and male 
mice (Figs 2F and 3E). In the acquisition phase, there were no differences of exploration levels between the 
TTC9A−/− and TTC9A+/+ of both the female and male mice (t(10–12) < 1.673, p = n.s.). For the time ratio of dis-
crimination between the novel and the familiar objects, no significant effects were found in both the TTC9A−/− 
female and male (short-term memory phase: t(10–12) < 1.016, p = n.s.; long-term memory phase: t(10–12) < 1.606, 
p = n.s.) mice as compared to the TTC9A+/+ animals (Figs 2G and 3F).
TTC9A−/− mice did not exhibit hedonism. In the sucrose preference test, TTC9A gene deletion 
had no significant effect on the amount of sucrose intake (t(10) < 1.297, p = n.s.), level of water consumption 
(t(10–12) < − 0.149, p = n.s.), and percentage of sucrose preference (t(10–12) < 1.322, p = n.s.) in both the female and 
male mice of TTC9A−/− and TTC9A+/+ animals (Figs 2H and 3G). In addition, there was no difference in the 
average body weight (t(10–12) < 0.852, p = n.s.) between the TTC9A−/− and TTC9A+/+ mice of both the female 
(TTC9A−/−: 21.79 ± 0.46 g; and TTC9A+/+: 22.60 ± 0.40 g) and male (TTC9A−/−: 31.05 ± 1.03 g; and TTC9A+/+: 
29.63 ± 1.37 g) animals.
TTC9A−/− mice did not exhibit increase in behavioral despair. In the forced swimming test, no 
significant changes were found in the immobility (t(10) = 0.525, p = n.s.) and swimming in TTC9A−/− female 
mice (t(10) = − 0.957, p = n.s.) (Fig. 2I); however, there was a marginal increase in climbing behavior (t(7) = 2.389, 
p = 0.048) of the TTC9A−/− female mice when compared to the TTC9A+/+ animals, indicating the enhancement 
of noradrenergic neurotransmission in mediation of anxiogenic response. In TTC9A−/− male mice, no difference 
was found in immobility (t(13) = − 1.747, p = n.s.), swimming (t(13) = 1.042, p = n.s.), and climbing (t(13) = 0.974, 
p = n.s.) behaviors as compared to the TTC9A+/+ male animals (Fig. 3H).
Effect of TTC9A−/− on behavioral response to estrogen treatment. Before ovariectomy, the ani-
mals were tested for their anxiety-related and exploratory behaviors. In open-field test, there was no significant 
difference in time-spent between the TTC9A−/− and TTC9A+/+ female mice in the center (t(17) = 1.223, p = n.s.) 
and periphery (t(20) = 1.68, p = n.s.) zones (Fig. 4D,E). However, TTC9A−/− female mice displayed significant 
increase in immobility (t(18) = − 3.342, p = 0.004) and time-spent in the corner zone (t(16) = − 2.867, p = 0.011) 
compared to the TTC9A+/+ mice (Fig. 4C,F), indicating anxiogenic response. In addition, we found no signifi-
cant difference in the distance moved (t(17) = 0.813, p = n.s.) of the TTC9A−/− (4334 ± 531.2 mm) and TTC9A+/+ 
(4907 ± 467.5 mm) female mice, suggesting that the immobility behavior was not due to general locomotor 
deficits (Fig. 4B). Furthermore, TTC9A−/− mice showed a significant increase in immobility duration (t(22) = 
− 3.031, p = 0.006), and a decrease in rearing frequency (t(23) = 4.088, p < 0.001) in the novel-cage exploration 
test (Fig. 4G,H). In the social interaction test, we found a decrease in the duration of social interaction behav-
ior (t(10) = 5.239, p < 0.001), but no changes were demonstrated in their interaction frequency (t(11) = − 0.739, 
p = n.s.) between TTC9A−/− and TTC9A+/+ female mice (Fig. 4I). In sucrose preference test, no difference was 
revealed in the amount of sucrose intake (t(24) = 1.037, p = n.s.), the level of water consumption (t(25) = − 0.612, 
p = n.s.), and the percentage of sucrose preference (t(25) = 0.704, p = n.s.) in TTC9A−/− mice as compared to the 
TTC9A+/+ animals (Fig. 4J). Additionally, there was also no change in the average body weight (t(24) = − 0.232, 
p = n.s.) of TTC9A−/− (21.4 ± 0.38 g) and TTC9A+/+ (21.6 ± 0.46 g) female mice. Altogether, these data are in line 
with the behavioral study in the earlier experiment.
As our previous study showed the TTC9A negatively regulates estrogen action in mammary development, we 
tested the hypothesis whether the effect of TTC9A gene deletion on anxiety is also related to its effect on estrogen 
response in female mice. This would be done by examining the effect of estrogen on anxiety-like behaviors in ova-
riectomized (OVX) mice. After ovariectomy, mice were given a 10-day recovery period and subsequently injected 
with either sesame oil (CTRL) or 17-β -estradiol benzoate (EB) in sesame oil. Twenty four hours after injection, 
two-way ANOVA showed no significant difference in the interaction, genotype, and treatment in the duration 
of time-spent in the open-arm (F(1,18) < 1.25, p = n.s.); however, TTC9A−/− OVX-EB mice showed an increase 
in closed-arm duration (p = 0.02) in the elevated plus-maze (Fig. 5A,B). Analysis of the number of entries to 
closed or open arm showed no significant difference in interaction, genotype, and treatment (closed: F(1,21) < 0.36, 
open: F(1,22) < 2.66), all p = n.s.; data not shown). In cylinder test, two-way ANOVA with post-hoc analysis also 
revealed no significant difference in genotype (F(1,19–20) < 0.412), p = n.s.), treatment (F(1,19–20) < 0.179, p = n.s.) 
and their interactions (F(1,19–20) < 1.266), p = n.s.) for immobility and rearing behaviors in the cylinder environ-
ment (Fig. 5C,D).
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Figure 2. Behavioral phenotypes characterization in TTC9A−/− female mice. A schematic diagram 
represents the time-line of the experimental design for behavioral study 1 (A). Effects of TTC9A−/− on a set 
of behavioral battery testing for anxiety-related and exploratory behaviors ((B) home-cage emergence test; 
(C) novel-cage exploration test; (D,E) rat-cage exploration test); memory function ((F,G) object recognition 
test); hedonia ((H) sucrose preference test); and behavioral despair (I, forced swimming test) in female mice. 
Note. The deletion of TTC9A gene induced anxiety-like behavior; and no significant difference were found in 
the memory function, hedonia, and behavioral despair measures. The data were presented as mean ± S.E.M. 
Indication: *Represents p < 0.05, **Represents p < 0.01.
www.nature.com/scientificreports/
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Forty eight hours after injection, in the home-cage emergence test, two-way ANOVA revealed a significant dif-
ference in interaction (F(1,21) = 17.05, p = 0.0005), but not in genotype or treatment (F(1,21) = 0.29 and F(1,21) = 0.01, 
respectively, all p = n.s.). Post-hoc analysis showed a significant reduction on the escape latency (p < 0.01) in 
TTC9A+/+ OVX-EB group as compared to the TTC9A+/+ OVX-CTRL animals, indicating an EB-induced anx-
iolytic effect in the home-cage emergence test. There was also a significant decrease of escape latency in the 
TTC9A−/− OVX-CTRL mice compared to TTC9A+/+ OVX-CTRL mice (p < 0.01). Interestingly, we found an 
increase of escape latency in the home-cage emergence test in TTC9A−/− OVX-EB treated mice compared to 
Figure 3. Behavioral phenotypes characterization in TTC9A−/− male mice. Effects of TTC9A−/− on a set of 
behavioral battery testing for anxiety-related and exploratory behaviors ((A) home-cage emergence test;  
(B) novel-cage exploration test; (C,D) rat-cage exploration test); memory function ((E,F) object recognition 
test); hedonia ((G) sucrose preference test); and behavioral despair ((H) forced swimming test) in male mice. 
Note, despite TTC9A−/− increased rearing behavior (marginal effect; p = 0.041) in the novel-cage exploration 
test, no significant differences were found in the overall anxiety, memory function, hedonia, and behavioral 
despair measures. The data were presented as mean ± S.E.M. Indication: *Represents p < 0.05, ***Represents 
p < 0.005.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:37568 | DOI: 10.1038/srep37568
Figure 4. Behavioral phenotypes characterization in TTC9A−/− female mice. A schematic diagram 
represents the time-line of the experimental design for behavioral study 2 (A) with manipulation of ovariectomy 
(OVX) procedure and 17-β -estradiol benzoate (EB) treatment. A new batch of TTC9A−/− female mice were 
generated and tested for mood- and anxiety-related behaviors. TTC9A−/− animals consistently showed anxiety 
in the open-field test with increased immobility duration and time-spent in the corner zone (C,F); as well as 
increased immobility and reduced rearing frequency in the novel-cage exploration test (G,H). Interestingly, 
there was an overall reduction on social behavior in the social interaction test (I), and no significant change 
was found on the sucrose preference test which measured the level of hedonia (J). The data were presented as 
mean ± S.E.M. Indication: *Represents p < 0.05, **Represents p < 0.01, ***Represents p < 0.005.
www.nature.com/scientificreports/
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TTC9A−/− OVX-CTRL and TTC9A+/+ OVX-EB animals (p < 0.05). In tail-suspension test, two-way ANOVA 
revealed a significant difference between treatments (F(1,23) = 6.61, p = 0.017), but no difference between gen-
otypes or interactions (F(1,23) = 0.96 and F(1,23) = 3.90, respectively, all p = n.s.). Post-hoc analysis showed a sig-
nificant increase of tail-suspension immobility in the TTC9A−/− OVX-EB treated mice as compared to the 
TTC9A−/− OVX-CTRL (p < 0.01) and TTC9A+/+ OVX-EB (p < 0.05) animals. This suggests that TTC9A−/− mice 
are susceptible to estrogen-induced anxiety-like behaviors (Fig. 5E,F).
Effect of TTC9A gene KO on the expression of TPH and 5-HTT mRNA in TTC9A−/− mice. It has 
been reported that EB treatment increases the expression of TPH1 and TPH2 in the dorsal raphe nucleus, which 
Figure 5. Effects of estrogen regulation on TTC9A−/−. A set of bar graphs showing the behavioral data for 
mood- and anxiety-related measures of TTC9A−/− female mice after ovariectomy (OVX). Animals were injected 
with either 17-β -estradiol benzoate (EB) or CTRL, and subsequently tested in the elevated plus-maze (A,B), 
cylinder test (C,D), home-cage emergence test (E), and tail-suspension test (F) in the following time order of 
24, 26, 48, and 52 h after injection. Interestingly, there were remarkable effects on anxiety (E) and behavioral 
despair (F) after 48 and 52 h in the TTC9A−/− OVX-EB mice. In the TTC9A+/+ animals, EB treatment reversed 
the anxiety-like behavior in the home-cage emergence test, while no difference was observed in the immobility 
measures of tail-suspension test. The data were presented as mean ± S.E.M. Indication: #Significant difference 
from the respective group of OVX-CTRL treated mice; *Significant difference from the TTC9A+/+ OVX-CTRL 
mice; and †Significant difference from the TTC9A−/− OVX-CTRL treated mice; (p < 0.05).
www.nature.com/scientificreports/
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in turn regulates serotonin synthesis22,23. As serotonergic system is fundamentally important in anxiety disor-
ders24,25, we investigated if the changes in mRNA expression levels of TPH1, TPH2, and 5-HTT in the vmPFC and 
the DRN of TTC9A−/− mice would be the reason for increased anxiety-like behaviors.
Two-way ANOVA of the gene expression in vmPFC, revealed a significant difference in genotype for TPH1 
(F(1,23) = 10.14, P = 0.004) and TPH2 (F(1,21) = 10.68, p = 0.004), and significant difference in treatment for TPH2 
(F(1,21) = 4.64, p = 0.043). Post-hoc analysis revealed significantly higher levels of TPH1, TPH2, and 5-HTT 
mRNA in the vmPFC of TTC9A−/− OVX-CTRL animals (5-HTT: p < 0.05; TPH1 & TPH2: p < 0.01) as com-
pared to the TTC9A+/+ OVX-CTRL group (Fig. 6A–C). Furthermore, EB treatment reduced significantly the 
expression of TPH2 and 5-HTT, but not TPH1, in TTC9A−/− mice (p < 0.05; Fig. 6B,C). On the other hand, EB 
treatment had no effect on the expression of TPH1, TPH2 and 5-HTT in TTC9A+/+ mice.
Figure 6. Effects of TTC9A−/− on TPH and 5-HTT expression in the vmPFC and DRN. Relative mRNA 
expressions of TPH1 (A,D), TPH2 (B,E), and 5-HTT (C,F) in the ventromedial prefrontal cortex (vmPFC)  
and dorsal raphe nucleus (DRN) of TTC9A−/− and TTC9A+/+ ovariectomized mice that received either  
17-β -estradiol benzoate (EB) or CTRL treatment. Note: TTC9A−/− with EB injection down-regulated TPH2  
and 5-HTT in the vmPFC, while up-regulated TPH2 and 5-HTT in the DRN as compared to the TTC9A−/− 
OVX-CTRL treated animals. The data were presented as mean ± S.E.M. Indication: *Represents p < 0.05, 
**Represents p < 0.01.
www.nature.com/scientificreports/
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In the DRN, two-way ANOVA revealed significant difference between genotypes for TPH1 (F(1,21) = 5.42, 
p = 0.030) and 5-HTT (F(1,21) = 6.26, p = 0.021), and significant difference between treatments for TPH2 
(F(1,22) = 5.509, p = 0.028) and 5-HTT (F(1,21) = 6.53, p = 0.018). Post-hoc analysis revealed significantly higher lev-
els of TPH2 and 5-HTT mRNA in OVX-EB TTC9A−/− mice compared to TTC9A−/− OVX-CTRL mice (p < 0.05; 
Fig. 6E,F). Furthermore, there were significantly higher levels of TPH2 and 5-HTT mRNA, and lower levels of 
TPH1 mRNA in OVX-EB TTC9A−/− than in OVX-EB TTC9A+/+ mice (TPH1 and TPH2, p < 0.05; 5-HTT, 
p < 0.01; Fig. 6D–F).
Discussion
While TTC9A mRNA expression was highly detected in the brain, its function with estrogen in the regulation 
of mood and anxiety behavior has not been reported. The findings from the present study demonstrated that 
TTC9A−/− induced anxiogenic behavior with significant increase of escape latency in the home-cage emer-
gence test and increased immobility in the open-field test in the female, but not in the male, mice. Although 
we observed comparable escape latencies for male TTC9A+/+, male TTC9A−/−, and female TTC9A−/− in the 
home-cage emergence test, we cannot interpret that both the TTC9A+/+ and TTC9A−/− male mice were highly 
anxious as other behavioral tests showed no significant difference in their exploratory and anxiety-related behav-
iors. Furthermore, most rodent models demonstrate lower anxiety-like behavior in females, compared to males 
in the light-dark box test26, elevated plus-maze27, and elevated t-maze tests28. Given that there were no major 
differences between the TTC9A+/+ and TTC9A−/− male mice, and we argue that TTC9A−/− induced anxiogenic 
behavior is specific to female mice.
Our observation of anxiogenic behavior in female TTC9A−/− mice was further supported by a remarkable 
decrease of exploratory rearing behavior in both the novel-cage exploration and rat-cage behavior tests, as well as 
increase of immobility behavior in the open-field and rat-cage behavior tests. In addition, there was also a signifi-
cant decrease in the social behavior of the TTC9A−/− female mice. It is of note that while we found no remarkable 
difference in the time-spent of animals in the center zone of the open-field, we showed a significant increase of 
immobility and time-spent in the corner zone in open-field for TTC9A−/− female mice, which would indicate 
anxiety-like behavior. A possible explanation for this phenomenon could be due to a ‘minimal’ or ‘low’ level of 
anxiety response induced in the TTC9A−/− female mice which could possibly result in no significant changes 
in the open-field center zone duration. This observation is strongly supported by our previous studies in which 
we found no significant difference in the center zone of the open-field after serotonergic drugs treatment (e.g. 
buspirone, escitalopram) in a low-anxiety condition as compared to the high-anxiety condition25,29. Regardless, 
our findings provide evidence that TTC9A gene has an important role in modulating the anxiety-like behavior.
Reports have suggested that in peri- and post-menopausal period, the incidence of mood and anxiety disorder 
is relatively higher in women due to estrogen deficiency3. Estrogen replacement therapy has shown a beneficial 
effect in the peri- and post-menopause women in clinical studies including randomized double-blind trials20,30. 
Similarly, anxiety- and depressive-like behaviors can also be found in animal models with OVX, and this effect can 
be reversed by administration of EB regimen31–33. This behavioral alteration in female animals with reduced estro-
gen after OVX is generally considered a well-validated animal model for human post-menopausal mood-related 
disorder34,35. Consistent with the reported studies, EB treatment reduced the escape latency in TTC9A+/+ OVX 
mice. However, we observed no depressive-like behavior in the tail-suspension test in the TTC9A+/+ OVX-CTRL 
mice. This could be due to the short duration of EB treatment. Reports have suggested that some effects on behav-
ior can only be observed several months after ovariectomy36,37.
Since our previous data suggest that TTC9A negatively regulates estrogen action15,21, we investigated the effect 
of estrogen on the behaviors of TTC9A−/− mice following OVX. The anxiety-like behavior in TTC9A−/− mice 
following ovariectomy was generally similar to the TTC9A+/+ mice except for the decrease of the escape latency 
in TTC9A−/− mice in the home-cage emergence test. This suggests some functional interaction between TTC9A 
and estrogen, which is supported by the evidence, that TTC9A+/+ mice exhibited decrease in anxiety in the 
home-cage emergence test in response to EB, and that TTC9A−/− mice showed increased anxiety in both the 
home-cage emergence test and in the tail-suspension test after EB treatment. This implies that TTC9A modulates 
estrogen action on anxiety and depressive behaviors such that its absence leads to estrogen to exert an anxiogenic 
effect.
The serotonergic system is important in mood and anxiety disorders and effective antidepressant therapy 
commonly uses drugs that increase the extracellular concentration of 5-HT6,38. Serotonergic neurons are found 
in the DRN and project their fibers to the forebrain regions including the prefrontal cortex and limbic struc-
tures39,40. TPH1 and TPH2 are rate limiting enzymes for 5-HT synthesis and it has been reported that estrogen 
increased the expression of TPH1 and TPH2 in the DRN and this regulation is mediated by ERβ through an 
estrogen response element in the 5′ untranslated region22,41. Our results show a trend of increased TPH1, TPH2 
and 5-HTT expression in DRN in response to EB but the observation is not statistically significant. TTC9A gene 
deletion significantly increased the expression of TPH2 and 5-HTT in the DRN in response to EB. EB treat-
ment also inhibited the expression of TPH2 and 5-HTT in vmPFC of TTC9A−/− mice and this is not observed 
in TTC9A+/+ mice. In addition, TTC9A−/− OVX mice expressed higher levels of TPH1, TPH2 and 5-HTT in 
vmPFC than TTC9A+/+ OVX mice. Together, TTC9A appears to influence estrogen action on gene expression 
such that in its absence, estrogen is more active in repressing (in the case on vmPFC) or activating (in the case on 
DRN) the genes related to 5-HT synthesis or transmission.
Concerning the 5-HT mediated regulation of anxiety, there are several discrepancies of its gene expression 
within the DRN and vmPFC for mood and anxiety-like behaviors. However, our results corroborate previous 
findings that showed increased 5-HTT expression in the DRN42, and reduced TPH synthesis and 5-HTT function 
in the vmPFC in animal models of depression8,9. Furthermore, the increase of TPH43,44, with lower levels of 5-HT 
and its metabolite (5-hydroxyindoleacetic acid) in the DRN (or brainstem), as well as decreased 5-HTT binding 
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in the ventral PFC, have also been reported in patients with major depression and suicidal behaviors44–46. The 
plausible explanation for an increase of 5-HTT and TPH expression in the DRN of anxiogenic mice could be that 
it resulted from the upregulation of homeostatic responses to the deficiency in 5-HT release, dysfunctional recep-
tor activation, and/or hypoactive 5-HT synthesizing enzymes43,44,46. Nonetheless, the involvement of serotonergic 
system for anxiety-like behaviors is complex due to different existing neuronal subpopulations in the DRN and 
their multi-synaptic interactions. Nevertheless, the effects of TTC9A−/− on estrogen regulation of TPH1, TPH2 
and 5-HTT which influences anxiety-like behaviors will remain an interesting topic for future investigation.
In conclusion, our study showed for the first time that absence of TTC9A gene induced anxiety-like behavior 
in mice, and this response was substantially abolished after ovariectomy. We confirmed that TTC9A−/− OVX 
mice exhibited significantly higher level of anxiety and behavioral despair in response to EB than TTC9A+/+ OVX 
mice. In addition, TTC9A−/− heightened EB inhibition of TPH1, TPH2 and 5-HTT in vmPFC and strengthened 
EB induction of TPH2 and 5-HTT in DRN. Taken together, these findings provide novel insight into the role of 
TTC9A on estrogen modulation in the mood and anxiety disorders.
Methods
Subjects. 5 month-old mice were socially housed in the individual-ventilated cages on corncob bedding 
under controlled temperature (about 24–26 °C), humidity (60–70%), and 12/12-h light/dark cycle (lights off at 
19:00 h). Food and water were available ad libitum. All experimental procedures and methods were performed 
in accordance with the relevant guidelines and regulations, and approval from the Institutional Animal Care and 
Use Committee (IACUC), Nanyang Technological University, Singapore (Reference Number: ARF-SBS/NIE-A 
0169 AZ).
Generation of TTC9A knockout mice. The detailed description of generation of the TTC9A−/− mice has 
been previously described15,21. In brief, the TTC9A targeting vector was generated by replacing the TTC9A exon 
1 with a loxp flanked neomycin cassette, and electroporated into R1 mouse ES cells. The TTC9A heterozygous 
ES clones were microinjected into 8 cell stage mouse embryos isolated from C57BL/6J. The TTC9A chimeras 
were crossed to C57BL6/6J mice to generate TTC9A heterozygous mice. These TTC9A heterozygous mice were 
crossed to obtain the TTC9A homozygous mice.
Experimental design. Two systematic behavioral studies were used to evaluate the mood - and 
anxiety-related behaviors, and memory function in both the male and female TTC9A−/− and TTC9A+/+ mice. 
In behavioral study 1, home-cage emergence test, novel-cage exploration test, and rat-cage behavior test were 
used to measure the anxiety and rearing behaviors, object recognition test was applied to measure the short- and 
long-term memory functions; sucrose preference test was used to measure hedonic activity; and finally forced 
swimming test was used to assess behavioral despair (Fig. 2A). Throughout the behavioral experiments, estrous 
cycle was determined by vaginal swab cytology and only females in diestrus stage were included in the analysis.
Drug administration. 17-β -Estradiol benzoate (EB; Sigma-Aldrich, Missouri, USA) was dissolved in the 
sesame oil with 0.25% benzyl alcohol and injected subcutaneously at a dosage 10 μ g/kg in both the TTC9A−/− and 
TTC9A+/+ female mice. The selection of this dosage was based upon previous studies of dose-dependent effects 
of EB treatment on anxiety level in OVX rodents which producing physiological plasma levels of estradiol and 
anxiolytic behavior 48 h later47,48. The behavioral testing was conducted in accordance with the order of time after 
EB injection.
In behavioral study 2, a new set of female mice were subject to OVX procedure followed by treatment of either 
control (CTRL; injection of sesame oil with 0.25% benzyl alcohol) or estradiol benzoate (EB). Firstly, mice were 
assessed for their anxiety and rearing behaviors using the open-field test, novel-cage exploration test, social inter-
action test, and sucrose preference test. Ten days after recovery from OVX surgery, all animals were injected with 
either CTRL or EB, and subjected to behavioral testing on day 20 and 21. In this paradigm, mice were assessed 
for anxiety-related behaviors in the elevated plus-maze (24 h), cylinder test (26 h), and home-cage emergence test 
(48 h), and finally a tail-suspension test (52 h) was used to measure behavioral despair. Behavioral testing con-
ducted 24 h and 48 h after EB injection were based on previous studies demonstrating its promising effects on the 
behavioral responses and EB-induced synaptic plasticity changes47–49. The experimental design is presented in a 
schematic representation in Fig. 4A.
Surgical procedures. A detailed description of the surgical procedure has been previously reported50. In 
brief, the animals were ovariectomized and anesthetized using a combination of ketamine (75 mg/kg) and xyla-
zine (5 mg/kg) injected subcutaneously. After surgery, animals had a 10-day recovery period.
Behavioral testing and evaluation. All testing and analysis of animal behaviors were performed by 
researchers who were blind to the treatments and condition of testing. The tests for behavioral study 1 were con-
ducted during 20:00–00:00, while the tests for behavioral study 2 after OVX were performed in the time order of 
24 h, 26 h, 48 h, 52 h after injections during 20:00–01:00. Mice were given at least 30 min acclimatization in the 
room before testing. After each test the arena or set-up was cleaned with 70% ethanol and dried before the next 
mouse was tested.
Home-cage emergence test. The procedure of home-cage emergence test was performed as previously described 
with minor modifications51. In brief, a novel mouse home-cage was placed on a platform and the lid of the 
home-cage was removed. A grid was placed over the edge of the home-cage in order to make it easier for the 
mouse to leave the home-cage. The experimenters measured the escape latency (time taken for the mouse to 
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climb out of its cage onto the grid). If the mouse did not escape from its home-cage within 10 min, the session was 
ended, and the mouse was given a score of 600 s.
Novel-cage exploration test. The standard novel-cage exploration test was performed as previously described52. 
Mice were introduced into a standard plastic cage filled with fresh corncob bedding. The number of exploratory 
rearing was counted during a 5 min period by offline recorded video observation.
Rat-cage behavior test. The test was conducted in a standard rat cage (25 × 35 × 25 cm), with an open top and a 
dark floor. The behavior of each mouse was video recorded. The duration of immobility and frequency of rearing 
were analyzed for the total 5 min observation of the mice spent in the arena.
Object recognition test. The object recognition test was performed as previously described with minor modifica-
tions53. The test consists of a habituation phase, acquisition phase, and finally the test phases for short-term mem-
ory (1 h after acquisition phase), and long-term memory (24 h after short-term memory test) functions. In the 
habituation phase, mice explored an open-field arena (40 × 40 × 40 cm3) for 10 min. Next day, during acquisition 
phase, mice were presented with two identical objects (object A + object A) in the same open-field environment 
for a total duration of 3 min. After 1 h, mice were tested in the same arena with one familiar object and one novel 
object (object A + object B) in the short-term memory phase. On the next day (24 h later), the familiar object 
was replaced by another novel object in the long-term memory test phase (object C + object B). The positions 
of objects were counter-balanced across subjects and testing phase. The duration spent on exploration in each 
object was video recorded. The total duration of exploration time was considered as the sum of time spent at 
both objects. Discrimination index was calculated as follows, the exploration time (T) of the novel object minus 
the familiar object, then dividing this value by the total amount of exploration of the novel and familiar objects 
[DI = (TN − TF)/(TN + TF)]54.
Sucrose preference test. The sucrose preference test was performed as previously described with minor modifi-
cations51,55. One day prior to the test, animals were exposed to drink 1% sucrose solution and water for 1 h, and 
subsequently followed by food and water deprivation for 14 h. After 14 h fasting, mice were again given a choice 
between two bottles of 1% sucrose solution and water, and tested for the total duration of 1 h. To prevent side 
preference for water or sucrose consumption, the two bottles were counter-balanced during the pre-test and 
test sessions. The sucrose and water intake were calculated from the total amount sucrose solution or water con-
sumed (ml) by weighing the bottle pre- and post-testing session. The relative sucrose consumption was corrected 
for body weight of the animals (ml/kg). The sucrose preference was calculated as a percentage of the sucrose 
consumption with respect to the total amount of liquid intake. The animals were tested individually during the 
sucrose consumption, and they were placed back into their respective group-housing cage immediately after the 
test.
Forced swimming test. The testing was carried out using a transparent Plexiglas cylinder (height 30 cm × diame-
ter 10 cm). The cylinder was filled with tap water (25 ± 1 °C) to a depth of 10 cm. The testing procedure was per-
formed over two consecutive days as previously described51,56. In a pre-test session, each mouse was placed in the 
water for 15 min. The following day, the mouse was again tested in the cylinder containing water for 10 min and the 
behavior was recorded by a digital camera. The duration of the following behaviors was measured: “immobility” 
(no movements or small and infrequent movements performed solely to maintain the nose above the water), 
“swimming” (active swimming with the forepaws), and “climbing” (scratching of cylinder walls using both fore-
paws and hind paws).
Open-field test. The test was conducted in an enclosed square, made of white plastic box (40 × 40 × 40 cm3). 
Behavioral testing started after the mouse had been individually placed in the middle of the arena. A trial 
was stopped after 5 min and the behavior of each mouse was video recorded. The duration of immobility and 
time-spent in the different zones (center, periphery and corner) of the open-field were measured and analyzed as 
previously described with minor modifications29,57.
Social interaction test. The social interaction behavior was conducted in a Plexiglas rectangle box 
(25 × 35 × 25 cm) with a wire net (30 × 40 cm) as a separator between the two animals. Animals were allowed to 
freely interact in the arena and the time-spent interacting was video recorded58.
Elevated plus-maze test. The apparatus consisted of two open-arms (40 × 5 cm) and two closed-arms 
(40 × 5 × 10 cm) that extended from a common central platform (5 × 5 cm). The apparatus was elevated at a 
height of 50 cm from the floor. The mouse was placed in the central platform and individually tested for 5 min. 
The duration of time-spent and frequency of entry into the open- and closed-arms were measured.
Cylinder test. All mice were tested in the transparent Plexiglas cylinder (height 30 cm × diameter 10 cm) for 
a total of 5 min duration. The behavior of each mouse was video recorded and the frequency of rearing was 
analyzed.
Tail-suspension test. All mice were subjected to the tail-suspension procedure as previously described59 for a 
total duration of 5 min. The mice were suspended by hanging their tails with adhesive tape in an individual 
compartment of 40 cm from the floor. The duration of immobility was measured when mice were completely 
motionless.
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Southern blotting analysis and polymerase chain reaction (PCR) genotyping. The genomic DNA 
from ES cells or tail biopsies was digested with Sca I, separated on a 0.8% agarose gel and blotted onto a positively 
charged nylon membrane overnight. These membranes were then hybridized with the digoxigenin (DIG)-labelled 
5′ probe overnight, washed, then blocked with blocking buffer and finally probed with anti-DIG-alkaline phos-
phatase antibody at a 1:5000 dilution. These nylon membranes with digoxigenin-labelled nucleic acids were 
detected using chemiluminescent immunodetection methods. PCR was also used for routine mouse gen-
otyping and the following PCR conditions and primer pairs were used for this purpose: 94 °C (30 sec), 60 °C 
(30 sec), 72 °C (1 min) for 30 cycles and a final extension step at 72 °C (7 min). TTC9A allele primers: TTC9A-FP: 
5′ -CACACGAGTTCAAGAGCCAAGGG-3′ ; TTC9A-RP: 5′ -GCTTCAACCGTCTTGCTCTG-3′ . Neomycin 
primers: Neo-FP: 5′ -ACTGGGCACAACAGACGATCGG-3′ ; Neo-RP: 5′ - GGAAGCGGTCAGCCCATTCG-3′ .
Real-time PCR analysis. After behavioral study 2, all mice were sacrificed and their brains were harvested 
for real-time PCR analysis. The vmPFC and DRN were dissected in the cryostat CM3050 (Leica Microsystems, 
Wetzlar, Germany) according to the anatomical region of the Mouse Brain Atlas by Franklin and Paxinos, 2007. 
The brain regions of interest, namely the dorsal raphe nucleus and ventromedial prefrontal cortex were homog-
enised in cold TRIzol (Invitrogen, Carlsbad, USA) and total RNA was extracted using TRIzol reagent, chloro-
form:isoamyl-ethanol (24:1) and phenol:chloroform:isoamyl-ethanol (50:24:1; Sigma-Aldrich, St. Loius, USA), 
precipitated using isopropanol and washed with 75% ethanol in DEPC-treated water (Sigma-Aldrich, St. Loius, 
USA) before re-suspending in 0.2% DEPC-treated water. From this 2 μ g of total RNA was reverse transcribed 
using Superscript II reverse transcriptase (Invitrogen, Carlsbad, USA). Real-time PCR was performed with KAPA 
SYBR® FAST qPCR Master Mix (Kapa Biosystems, Wilmington, USA) on an ABI Prism 7000 sequence detection 
system (PE Applied Biosystems, Foster City, CA). The real-time PCR primers used were: tryptophan hydroxy-
lase (TPH) 1 (forward 5′ -GGGCTTGACTTTGTCTCTGC′ and reverse 5′ -GTTTGAATCTGGCCTGGTGT-3′ ), 
TPH2 (forward 5′ -CCTACACGCAGAGCATTGAA-3′ and reverse 5′ -CTAGGCATCAAATCCCCAGA-3′ ), 
serotonin (5-hydroxytryptamine; 5-HT) transporter (5-HTT) (forward 5′ -CTTCAGCCCCGGATGGTT-3′ 
and reverse 5′ -GTGGACTCATCAAAAAACTGCAA-3′ ), and Glyceraldehyde 3-phosphate dehydrogenase 
(GADPH) (forward 5′ -GTCGGTGTGAACGGATTTG-3′ and reverse 5′ -AATTTGCCGTGAGTGGAGTC-3′ ). 
Fold changes were calculated from the Ct values and the relative expression levels of the TPH1, TPH2, and 5-HTT 
were determined by normalizing their Ct values against GADPH Ct values.
Statistical analysis. Statistical analysis were performed using GraphPad Prism 7. All data are pre-
sented as mean ± S.E.M. Tests done in behavior study 1 were analyzed using independent sample t-tests. A 
repeated-measures analysis was used to measure the within- and between-subject components in the object rec-
ognition test. Tests done before EB injection in behavior study 2 were analyzed using independent sample t-tests. 
Tests done after EB injection were analyzed using a two-way ANOVA with LSD post-hoc test. Real-time PCR 
results were analyzed using two-way ANOVA with LSD post-hoc. All p-values < 0.05 were considered significant. 
Outliers were identified and removed using ROUT method.
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